ISN-001 is under clinical development by Anterogen and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ISN-001’s likelihood of approval (LoA) and phase transition for Muscle Injury took place on 23 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ISN-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ISN-001 overview

ISN-001 (ALLO-ASC) is under development for the treatment of perianal fistula, Crohn’s disease, burn wounds, diabetic foot ulcer, epidermolysis bullosa, severe pneumonia caused by the novel coronavirus infection, lateral epicondylitis, burn injury, tendon injury, and fecal incontinence. It is administered as intravenous infusion.

The drug candidate was also under development for the treatment of osteoarthrirtis.

Anterogen overview

Anterogen is a pharmaceutical company. The company is engaged in the research, development and marketing of cell therapy products. It offers Cupistem injection, an adipose-derived stem cell therapy product for the treatment of Crohn’s fistula; Queencell for the regeneration of subcutaneous adipose tissue; Adipocell for the treatment of depressed scars; and Remodulin injection for the treatment of pulmonary arterial hypertension. The company also provides services such as stem cell banking and analysis service. Anterogen operates in South Korea, where it is headquartered in Geumcheon-gu, Seoul, Republic of Korea (South Korea).

Quick View ISN-001 LOA Data

Report Segments
  • Innovator
Drug Name
  • ISN-001
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Other Diseases
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.